### This Page Is Inserted by IFW Operations and is not a part of the Official Record

#### **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.


Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

#### IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

### Figure 1







Figure 2



Patent Appn: "Novel Tumor-Associated Antigens" Inventors: Punnonen et al. Attorney Docket No. 334.210

Figure 3




Figure 4






Figure 5








pMaxVaX<sub>sEpCAM:CD28BP-15</sub> pMaxvaX<sub>sEpCAM:CD28BP-15</sub> pMaxVax<sub>sEpCAM</sub> Monocistonic vector



pMaxVax<sub>TAg-25:CD28BP-15</sub> bicistronic vector pMaxVax<sub>TAg-25</sub> monocistronic vector


Patent Appn: "Novel Tumor-Associated Antigens" Inventors: Punnonen et al. Attorney Docket No. 334.210

Figure 7



## Immunization

Figure 8



Patent Appn: "Novel Tumor-Associated Antigens" Inventors: Punnonen et al. Attorney Docket No. 334.210

Figure 9A





Figure 9B


Protein Vaccine:





Stimulation in vitro

Patent Appn: "Novel Tumor-Associated Antigens" Inventors: Punnonen et al. Attorney Docket No. 334.210

Figures 10A and 10B







 $\infty$ 

Immunization

Figure 11


		Pre-bleed	peed	1st [	1st DNA	2nd	2nd DNA	3rd DNA	NA	4th DNA	) ANC
DNA Treatment	Route	Responders to EpCAM	Responders Responders Responders Responders Responders to EpCAM to TAg25 to EpCAM to TAg25	Responders to EpCAM	Responders to TAg25	Responders to EpCAM	Responders	Responders Responders to EpCAM to TAg25 to EpCAM	Responders to TAg25	Responders to EpCAM	Responders to TAg25
Saline	Ë	0	0	0	0	0	0	0	0	0	0
EpCAM	p!	0	0	0	0	-	-	3	3	3	က
EpCAM	ш	0	0	1	0	2	2	2	2	2	2
TAg25	рį	0	0	0	0	0	0	3	3	3	3
TAg25	щ	0	0	0	1	1	1	4	4	4	4
		•						•			
	•										,

Monkeys were designated to be responders if their serum contained antibody levels that gave an EC50 of  $\geq$ 5 or an OD value of  $\geq$ 

0.5 at a 1/10 serum dilution by ELISA for either EpCAM or TAg25

The number of responders is out of a total maximum of 4 for EpCAM or TAg25 treated groups or 2 for the saline treated group

Figure 12




Reciprocal Serum Dilution after 4th immunization with DNA vector (1 mg/per dose)



Patent Appn: "Novel Tumor-Associated Antigens" Attorney Docket No. 334.210 Inventors: Punnonen et al.

Figure 13



immunization

vector sEpCAM TAg-25 vector


followed by delivery of 100 ug TAg-25 protein empty control vector Protein (delivery of 1mg DNA vector 4 times) DNA (delivery of

2 times)

(delivery of 1mg DNA vector/4 times followed by delivery of 100 ug TAg-25 protein 2 times) DNA + Protein Boost



Figure 14



DNA


After Last Protein Boost

Protein

DNA + Protein Boost

\* Significantly higher than negative ctrl





- (2x10<sup>6</sup>/ml) for 16-24hr +/- antigen in tubes Preactivate PBMCs
- with capture anti-IFNy Ab Coat PVDF membrane
- Block
- Add cells in quadruplicates
- Biotinylated capture Ab
- Streptavidin HRP
- Substrate AEC

# Readout: IFNy Spot Forming Cells






Positive Negative

Elispot reader system (Carl Zeiss) with KS Elispot Software 4.3

## Figure 16



## 2mg DNA 4x every 3 wks

DNA immunizations (n=5):

- Empty vector i.m. or i.d.
  - TAg25 i.m. or i.d.
- TAg25/hB7.1 i.m. or i.d.
- TAg25/CD28BP i.m. or i.d.
- TAg25 + control DNA i.m.
- TAg25 + hB7.1 i.m.
- TAg25 + CD28BP i.m.


## 100ug TAg25 protein in 2mg Alum 2x every 4wks; i.m. Given to 20 monkeys previously treated with DNA i.d.



Animal Species: Macaca fascicularis



Figure 17



Restimulation using a mixture of 9-11 lphalpha EpCAM-specific peptides


Figure 18

	Antigen-spec	Antigen-specific Response
Vaccine	CD4 T Cell *	CD4 & CD8 T Cell **
Empty vector	9/2	9/0
TAG25	1/5	0/5
TAg25/B7-1	0/5	0/5
TAg25/CD28BP	3/5	2/5

- Number of animals positive whenrestimulatedwith TAg25
- Number of animals that are positive forrestimulation with both TAG25 and EpCAM peptide mixture in separate cultures

> 10 spots above background is considered positive





Immunization: Empty vector

TAg25 2mg

2mg

2mg

Dose:


2mg

1mg + 1mg

4<sup>th</sup> DNA



Figure 20



2<sup>nd</sup> TAg25 Boost

